Low-grade serous epithelial ovarian cancer: a comprehensive review and update for radiologists

Amante, S; Santos, Filipa; Cunha, Teresa Margarida

doi:10.1186/s13244-021-01004-7

Cited by 15 publications

(10 citation statements)

References 31 publications

(155 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous subtypes of ovarian cancers differ in terms of their cell line, mode of origin, growth speed, and feasibility of early detection [ 23 ]. Hence, imaging findings can help predict malignancy through features suggestive of malignancy (e.g., lesion size, wall/septal thickness, papillary projections, lobulated mass, necrosis, and solid and cystic architecture) [ 24 ]. Benign ovarian tumors are more likely to show mild enhancement and fewer ascites than borderline and malignant ovarian tumors in MRI findings [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

The Discrepancy between Preoperative Tumor Markers and Imaging Outcomes in Predicting Ovarian Malignancy

Shin

Kim

Yoon

et al. 2022

Cancers

View full text Add to dashboard Cite

Preoperative tumor markers and imaging often differ in predicting whether an ovarian tumor is malignant. Therefore, we evaluated the correlation between the predictive values of imaging and tumor markers for diagnosing ovarian tumors, especially when there were discrepancies between the two. We enrolled 1047 patients with ovarian tumors. The predictive values and concordance rates between the preoperative risk of ovarian malignancy algorithm (ROMA) and imaging, including CT and MRI, were evaluated. Diagnoses of 561 CT (77.9%) and 322 MRI group (69.2%) participants were consistent with the ROMA. Among them, 96.4% of the CT (541/561) and 92.5% of the MRI (298/322) group predicted an accurate diagnosis. In contrast, 67.3% (101/150) of CT and 75.2% (100/133) of MRI cases accurately predicted the diagnosis in cases with discrepancies between ROMA and CT or MRI; a total of 32% (48/150) of the CT and 25.5% (34/133) of the MRI group showed an accurate ROMA diagnosis in cases with discrepancies between ROMA and imaging. In the event of a discrepancy between ROMA and imaging when ovarian tumor malignancy prediction, the question is which method should take precedence. This study demonstrates that MRI has the greatest diagnostic accuracy, followed by CT and ROMA. It is also important to understand underlying diseases and benign conditions and rare histopathologies of malignant tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

The Discrepancy between Preoperative Tumor Markers and Imaging Outcomes in Predicting Ovarian Malignancy

Shin

Kim

Yoon

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…The research of Amante et al explained that the tumor size radiologically in serous ovarian tumors was >5cm. 20 The radiologist should be aware of this entity and familiar with its radiological findings in order to optimize the imaging protocol in order to obtain appropriate treatment. The size of the tumor in this study, both unilateral and bilateral ovarian involvement, the results were the same, which was more commonly found in the size 8 cm and mostly found in the left ovary (25.6%).…”

Section: Discussionmentioning

confidence: 99%

The Relationship of SRY Determining Region Y Box 2 (SOX2) Immunohistochemical Expression with Stromal and Intratumoral TILs (Tumor Infiltrating Lymphocytes) in Patients with Ovarian Serous Tumors

Hasan¹,

Delyuzar²,

Intan³

et al. 2022

IJRP

View full text Add to dashboard Cite

Background: Ovarian serous tumors are the most common epithelial tumors in premenopausal and postmenopausal, 60% of the most common cases are ovarian cystadenoma, 25% of low grade and highgrade serous carcinoma. Tumor infiltrating lymphocytes (TILs) is used to predict the prognosis some solid tumors. SRY (sex determining region Y)-box 2 (SOX2) is a transcription factor. High SOX2 in ovarian tumors associated with reduced disease-free survival. Research Objective: To determine the relationship between SOX2 expression and TILs in patients with a diagnosis of ovarian serous tumor at the Anatomic Pathology Laboratory, USU Medical Faculty and RSUP. H. Adam Malik Medan. Materials and Methods: 39 samples histopathological slides with a diagnosis of ovarian serous tumor, slide review was performed and TILs assessed and then SOX2 immunohistochemical staining and then analyzed for correlation between variables using Eta test (p<0.001) and Somer'sd test (p=0.120). Results:The highest expression of SOX2 high was in the highgrade serous carcinoma subtype in 9 (23.1%) cases. Most cases were also found in low SOX2 expression with low iTILs in 20 (51.3%) cases and low SOX2 expression with low sTILs in 16 (41.0%) cases. There was a significant relationship between subtypes and SOX2 expression (p < 0.001) and the Somers'd correlation showed no significant relationship between SOX2 and TILs (p = 0.120). Conclusion:In this study, there was a correlation between tumor subtypes and SOX2 expression and there was no correlation between SOX2 expression and TILs in ovarian serous tumors.

show abstract

“…Although most patients with low-grade serous carcinoma present at an early stage, they do occasionally present at an advanced stage, and in this case, although the initial treatment may lead to a complete response, relapse is common with poor response to chemotherapy [13]. Low-grade serous carcinomas are often characterized by BRAF, KRAS, NRAS, EIF1AX, and USP9X mutations [14].…”

Section: Serous Carcinomasmentioning

confidence: 99%

The Role of Omics Approaches to Characterize Molecular Mechanisms of Rare Ovarian Cancers: Recent Advances and Future Perspectives

et al. 2021

View full text Add to dashboard Cite

Rare ovarian cancers are ovarian cancers with an annual incidence of less than 6 cases per 100,000 women. They generally have a poor prognosis due to being delayed diagnosis and treatment. Exploration of molecular mechanisms in these cancers has been challenging due to their rarity and research efforts being fragmented across the world. Omics approaches can provide detailed molecular snapshots of the underlying mechanisms of these cancers. Omics approaches, including genomics, transcriptomics, proteomics, and metabolomics, can identify potential candidate biomarkers for diagnosis, prognosis, and screening of rare gynecological cancers and can aid in identifying therapeutic targets. The integration of multiple omics techniques using approaches such as proteogenomics can provide a detailed understanding of the molecular mechanisms of carcinogenesis and cancer progression. Further, omics approaches can provide clues towards developing immunotherapies, cancer recurrence, and drug resistance in tumors; and form a platform for personalized medicine. The current review focuses on the application of omics approaches and integrative biology to gain a better understanding of rare ovarian cancers.

show abstract

Low-grade serous epithelial ovarian cancer: a comprehensive review and update for radiologists

Cited by 15 publications

References 31 publications

The Discrepancy between Preoperative Tumor Markers and Imaging Outcomes in Predicting Ovarian Malignancy

The Discrepancy between Preoperative Tumor Markers and Imaging Outcomes in Predicting Ovarian Malignancy

The Relationship of SRY Determining Region Y Box 2 (SOX2) Immunohistochemical Expression with Stromal and Intratumoral TILs (Tumor Infiltrating Lymphocytes) in Patients with Ovarian Serous Tumors

The Role of Omics Approaches to Characterize Molecular Mechanisms of Rare Ovarian Cancers: Recent Advances and Future Perspectives

Contact Info

Product

Resources

About